Presentations Search presentations Synthetic Receptor Enabled Differentiation (ShRED), a novel platform for manufacturing of iPSC-derived cytotoxic innate lymphocytes for “off-the-shelf” cancer immunotherapies November 11, 2022 VivoVec lentiviral vector particles surface-engineered with T cell activating and co-stimulatory ligands enhance in vivo CAR T cell generation and antitumor activity November 11, 2022 In vivo generation of universal CAR T cells that mediate durable anti-tumor immunity through combinatorial targeting with bispecific small molecule adaptors November 10, 2022 Engineering iPSCs with Synthetic Receptors to Drive Differentiation Compatible with Scale-Up July 28, 2022 A Synthetic Cytokine Receptor Platform for Producing Cytotoxic Innate Lymphocytes as Off-the-Shelf Cancer Therapeutics May 24, 2022
